Selinexor Enhances NK Cell Activation Against Malignant B Cells via Downregulation of HLA-E.

ABSTRACT: Selinexor is an FDA approved selective inhibitor of the nuclear export protein exportin-1 (XPO1) and causes specific cancer cell death via nuclear accumulation of tumor suppressor proteins. Design of rational studies for the use of selinexor in combination with other therapeutic agents, such as immunotherapies, requires a fundamental understanding of the effects of selinexor on the immune system. One important emerging area of immunotherapy are natural killer (NK) cell based therapeutics. NK cell function is tightly regulated by a balance of signals derived from multiple activating and inhibitory receptors. Thus in cancer, up-regulation of stress ligands recognised by activating receptors or down-regulation of HLA class I recognised by inhibitory receptors can result in an anti-canc

SUBMITTER: Fisher JG 

PROVIDER: S-EPMC8672299 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature